Objective: To examine associations between aggregate genetic risk and Alzheimer disease (AD) markers in stages preceding the clinical symptoms of dementia using data from 2 large observational cohort studies.
Genetic variants have a large influence in sporadic AD dementia, with heritability estimates exceeding 60%. 4 In addition to the APOE gene, 5 to date 21 common genetic variants have been associated with AD in large genome-wide association study (GWAS) meta-analyses. 6 However, the effect sizes of these variants are small (odds ratios , 1.22) , and recent work suggests that numerous additional loci distributed throughout the genome explain a much larger portion of the variance than the select few that surpass GWAS-level significance thresholds. [7] [8] [9] For instance, GWAS-confirmed loci account for 2% of the variance in discriminating patients with AD dementia and controls, beyond the 6% accounted for by APOE, whereas examination across the remaining 2 million common genetic variants explains an additional 25% of the variance. 9 Thus, aggregation across a large number of loci is likely a more sensitive method to establish underlying genetic risk to AD dementia than solely examining loci surpassing stringent GWAS-level significance thresholds.
Although the accumulation of the b-amyloid (Ab) protein is likely a central event in AD development, 10 mechanistic pathways not directly linked to Ab have been increasingly implicated in common genetic risk loci of AD, such as processes related to the immune system and cytoskeletal function. [11] [12] [13] [14] Given the involvement of nonamyloid pathways in common AD genetic risk loci, it is possible that genetic variants influence AD markers early in the lifespan, before amyloid accumulation has begun.
We sought to derive measures of polygenic risk based on the results from the recent large meta-analysis of AD dementia from the International Genomics of Alzheimer's Project (IGAP) and determine whether these polygenic risk scores (PGRS) were associated with AD-relevant markers during the stages preceding dementia among older participants, but also early in the lifespan among younger participants. Understanding the early influence of genetic risk will provide important insights into mechanisms of AD development throughout the lifespan as well as improve detection of at-risk individuals before clinical symptoms and widespread neuronal damage has ensued.
METHODS Participants. Our analyses included older clinically normal (CN) participants, patients with mild cognitive impairment (MCI), and patients with AD dementia from the Alzheimer's Disease Neuroimaging Initiative study (ADNI), 15 as well as younger CN participants from the Brain Genomics Superstruct Project (GSP) 16, 17 , and CDR $0.5. Diagnoses were determined using each participant's baseline visit (clinical progression from baseline was not considered). ADNI1 participants were included in the current analysis if they had genotyping data available and were of European ancestry (n 5 166 AD, 332 MCI, and 194 CN). ADNI2 participants were included if they had genotyping data available, were of European ancestry, underwent florbetapir PET, and were not included in ADNI1 analyses (n 5 332 MCI and 173 CN). GSP participants were healthy volunteers in a Boston area imaging study and between 18 and 35 years old. GSP participants were included if they had genotyping data available, were of European ancestry, and had structural MRI data available (n 5 1,322).
Standard protocol approvals, registrations, and patient consents. Institutional review boards approved study procedures across participating institutions. Written informed consent was obtained from all participants.
GWAS processing. Genotyping procedures are described elsewhere for the ADNI 18 and GSP. 19 Genotyping data from the Illumina Human610-Quad BeadChip was used for ADNI1, Illumina Omni 2.5 M platform for ADNI2, and Illumina Infinium Human OmniExpress for GSP. All analyses were restricted to participants with non-Hispanic European ancestry, as identified with multidimensional scaling analysis performed in combination with the 1000 Genomes sample 20 and performed within each genotyping platform separately.
Standard quality control procedures were applied to GWAS data using PLINK v1.9 (https://www.cog-genomics.org/plink2). Individuals were excluded for missing genotype rates .5% and sex inconsistency. Single nucleotide polymorphisms (SNPs) were excluded if minor allele frequency was ,0.01, genotype call rate was ,95%, Hardy-Weinberg Equilibrium deviation (p , 1 3 10
26
), and ambiguous strand information. Nongenotyped SNPs were imputed using MiniMac35, with the 1000 Genomes European participants as the reference sample and following the Minimac cookbook instructions. 21 Computation of PGRS. We computed PGRS using PLINK's profile function, which computes the sum of reference allele counts at each SNP weighted by the log odds ratio from the stage 1 analysis of the IGAP GWAS, which contrasted 17,008 patients with AD dementia with 37,154 CN controls. 6 Critically, the summation was constrained to independent loci with an IGAP stage 1 p value below a threshold. The independent loci were identified using PLINK's linkage disequilibrium (LD) clumping procedure (with 0.5 as the LD threshold), which reveals correlated sets of SNPs. LD clumping ensures that large blocks of correlated SNP sets do not overwhelm the PGRS computation. However, we also repeated analyses using PGRS calculations that included chromosome 19. Importantly, the ADNI participants used in the current analysis were not included in the IGAP stage 1 analysis that generated the summary statistics file. To select a PGRS for subsequent analyses within CN and MCI, we examined the p value threshold that best differentiated patients with AD dementia from older CN participants within the ADNI1 sample. PGRS were z-transformed based on the distribution of values within CN.
Ab markers. Associations with Ab were examined in 2 independent groups without dementia from ADNI. First, we examined this association within a subset of ADNI1 participants with CSF data 22 (n 5 272). Given the small sample size of this subset, we additionally explored associations with Ab within 505 participants without dementia who underwent florbetapir PET imaging in ADNI2. 23 Participants were only included in this analysis if they were not used in the ADNI1 CSF analysis to ensure an independent sample. Since ADNI1 and ADNI2 samples underwent genotyping on different platforms, analyses were performed separately within each group.
Structural MRI acquisition and processing. Acquisition and processing of structural MRI scans have been described previously. 19, 24 A longitudinal Freesurfer version 4.3 pipeline was used to extract hippocampus volume (HV) for ADNI1, while a crosssectional Freesurfer version 4.5 pipeline was used for GSP. HV was adjusted by total intracranial volume and additionally adjusted for coil type within GSP (12 vs 32 channel).
Statistical models. Statistical analyses were performed using R v3.0 (http://www.r-project.org/). Linear mixed models were used to assess baseline and longitudinal effects in cognitive factor scores (memory and executive function) 25, 26 and HV (mean neuropsychological follow-up 4.58 6 2.74 years; mean follow-up for HV 2.97 6 1.22 years). Linear mixed models included a random intercept and slope for each participant. Risk of clinical progression (CN to MCI/AD or MCI to AD) within 3 years of follow-up was examined with logistic regression. Multiple regression was used to assess the association between PGRS and HV within GSP where only baseline data were available.
All analyses controlled for APOE4, age, and sex, as well as 5 principal components from a multidimensional scaling analysis to account for population heterogeneity. Analyses within ADNI participants without dementia additionally controlled for diagnosis (CN vs MCI). The interaction between each covariate and time was included in linear mixed models. Education was controlled in models examining cognition. The p values were 2-sided and no multiple comparisons correction was performed.
RESULTS Participant demographics are listed in table 1. Given that the number of SNPs used to calculate a PGRS is arbitrary (table e-1), we first examined the ability of different PGRS iterations to discriminate between 166 patients with AD dementia and 194 older CN from ADNI1. Interestingly, discrimination between patients with AD dementia and older CN participants from ADNI1 dramatically increased between very stringent p values and p 5 0.01, and reached a plateau after p 5 0.01 (figure 1). Based on this pattern, we examined a liberally defined PGRS using the p 5 0.01 threshold in follow-up analyses.
Within the ADNI1 group without dementia (older CN and MCI combined, n 5 526), linear mixed models were conducted to assess associations with baseline and longitudinal change in memory, executive function, and HV (table 2) . There was a main effect of PGRS on memory (p 5 0.002), such that elevated PGRS was associated with worse baseline memory performance (figure 2A). The main effect of PGRS on baseline executive function was not significant (p 5 0.32; figure 2B ). Finally, there was a main effect on HV, such that higher PGRS was associated with smaller baseline HV (p 5 0.002, figure 2C ). PGRS accounted Baseline and longitudinal change in cognition and hippocampus volume was examined within ADNI1 participants without dementia. A subset analysis was performed within the ADNI1 participants without dementia to examine associations between polygenic risk score (PGRS) and b-amyloid (Ab) status in the subset of this group that had CSF data available (n 5 272). Additional analyses examining PGRS vs Ab status was performed in an independent sample of participants without dementia who underwent florbetapir scanning at ADNI2 (these participants were not used in the analysis relating CSF Ab to PGRS). Within the ADNI1 sample, 26/526 participants were missing hippocampus volume data. The GSP cohort was used to examine the association between baseline hippocampus volume and PGRS in a sample of young CN participants. APOE41 participants carry at least 1 e4 allele.
for 2.3% of the variance in baseline memory and 2.0% of the variance in baseline HV. Within these linear mixed models, the interaction between PGRS and time was significant for both memory (p 5 0.0005) and executive function (p 5 0.01), such that higher PGRS was associated with greater rate of decline across both domains (figure 2, D and E, table 2). The association between PGRS and change in HV did not reach statistical significance (p 5 0.06, figure 2F ). PGRS accounted for 3.2% of the variance in longitudinal memory, 1.4% of the variance in longitudinal executive function, and 1.1% of the variance in longitudinal HV.
Examination of clinical progression within 3 years of follow-up (CN to MCI/AD or MCI to AD) revealed progression in 15 of the 194 ADNI1 CN and 143 of the 332 ADNI1 MCI. In a logistic regression model, PGRS was associated with increased risk of progression within 3 years (p , 0.00001, table 2, figure e-1).
Given that PGRS was significantly associated with baseline HV, cognitive decline over time, and clinical progression, models were repeated with PGRS and baseline HV as simultaneous predictors of cognitive decline and clinical progression. This analysis revealed We next examined associations between PGRS and Ab in the subset of 272 ADNI1 participants without dementia with CSF data available (table 2). Although higher PGRS were associated with lower (e.g., more AD-like) CSF Ab levels, this analysis did not reach statistical significance (p 5 0.11, figure 3A) . Given the smaller sample size of this CSF analysis, we additionally examined an independent sample of 505 participants without dementia who underwent florbetapir PET imaging in ADNI2. This analysis revealed a similar association such that elevated PGRS was associated with greater (e.g., more AD-like) levels of florbetapir Ab (p 5 0.03, figure 3B ). Across both analyses, PGRS accounted for 1.0% of the variance in Ab levels.
Finally, we examined the association between PGRS and cross-sectional HV within a large younger cohort (age 18-30 years, n 5 1,322). This analysis revealed a marginal association, such that higher PGRS was associated with smaller HV (p 5 0.05; PGRS explained 0.2% of the variance in HV).
All analyses were repeated using PGRS that included chromosome 19 and revealed similar results (table e-2). Analyses were also repeated using a more conservative PGRS that only incorporated the smaller set of loci meeting statistical significance in the large IGAP meta-analysis (table 2, table e-2) . Interestingly, there were no significant associations with cognition or biomarkers using this conservatively defined PGRS, with the exception of baseline memory (p 5 0.01).
DISCUSSION Among older participants without dementia, PGRS were associated with multiple AD markers. Specifically, higher PGRS was associated with worse memory, smaller HV, and AD-like levels of Ab at baseline. We also found that higher PGRS was associated with greater longitudinal change in both memory and executive function, as well as elevated risk of clinical progression. Within a large sample of young clinically normal adults under age 35 years, we found that higher PGRS was associated with smaller HV, suggesting that an effect of aggregate genetic risk is not specific to processes occurring in late life. Importantly, this pattern of results was only present when PGRS calculations incorporated many loci below GWAS-level significance. Overall, these analyses provide evidence that aggregate genetic risk of AD dementia exerts effects that are detectable before the clinical symptoms of dementia are present, even among young adults.
The added sensitivity gained in our analyses by summing across a large number of genetic loci is 
(PGRS) discrimination between patients with Alzheimer disease (AD) dementia and older clinically normal (CN) participants
Multiple PGRS iterations were examined that incorporated different quantities of loci based on p value significance thresholds from the large International Genomics of Alzheimer's Project (IGAP) meta-analysis. Significance is shown on the y-axis (negative log p value), and corresponds to the independent contribution of PGRS in predicting diagnosis in our analysis of Alzheimer's Disease Neuroimaging Initiative patients with AD dementia compared to CN participants (controlling for APOE4, age, sex, and 5 multidimensional scaling principal components). The x-axis shows the p value threshold applied to the IGAP summary statistics file to determine which single nucleotide polymorphisms (SNP) to include in each PGRS iteration. The effect using a threshold of p 5 0.01 is shown by the gray filled diamond. The horizontal dashed line reflects the significance value corresponding to a conservative PGRS that only incorporated 18 SNP that were significant in the IGAP meta-analysis.
consistent with work examining heritability within AD 7-9 as well as studies investigating highly heritable psychiatric disorders that are associated with risk loci that individually exert small effects. 27, 28 This pattern implies that restricting analyses to a small number of risk loci provides a weak signal of underlying genetic risk that is improved by aggregating effects across many loci. Our results might further explain discrepancies reported across exploratory GWAS studies of AD markers. For instance, the top genome-wide significant loci that emerged from an exploratory GWAS analysis of AD pathologies (Ab plaques and neurofibrillary tangles) were not significant at a liberal statistical significance threshold of p , 0.05 in the IGAP GWAS contrasting AD dementia to CN, 6, 29 highlighting that the top loci surpassing GWAS level significance thresholds in analyses examining different AD phenotypes are likely to differ. Thus, although it is necessary to apply stringent criteria in discovery style GWAS analyses to reduce the incidence of false-positives, it is highly likely that relevant signal exists below these stringent criteria. 9 Within older participants without dementia, PGRS was associated with cognitive decline, highlighting that elevated genetic risk influences longitudinal trajectories even among individuals without dementia. This finding is consistent with work across multiple laboratories linking early cognitive decline to established AD risk factors, such as elevated amyloid 30 and the APOE4 genotype, 31 as well as work showing an association between cortical thickness and polygenic risk within CN participants (even among Ab2 CN participants). 32 However, our findings are at odds with a previous study that did not find an association between liberally defined PGRS and cognitive decline among a large sample of CN participants from the Cognitive Aging Genetics in England and Scotland consortium. 33 It is noteworthy that PGRS from that study was computed using an older GWAS of AD dementia with a much smaller discovery sample than the recent IGAP GWAS used in our analysis (3,941 patients with AD dementia vs 17,008 patients with AD dementia). 6, 34 The power of PGRS analyses is known to increase as discovery sample size increases. Nevertheless, it will be important to replicate the association between PGRS and cognitive decline in cohorts beyond ADNI.
We also found that liberal PGRS was associated with baseline HV within older adults without dementia. Although the association between PGRS and Ab in the subset of ADNI1 participants who had CSF data available (n 5 272) did not reach statistical significance (p 5 0.11), an independent analysis using ADNI2 florbetapir data in a much larger sample of participants without dementia (n 5 505) did reveal a significant association between PGRS and Ab. Importantly, the magnitude and direction of the effect was identical across the 2 independent samples, providing strong support for an association between PGRS and Ab among individuals without dementia and highlights the importance of large samples when performing analyses linking genetics with biomarkers. Although an association between Ab and PGRS was Table 2 Main findings as well as repeated analyses using a conservative polygenic risk score (PGRS) identified in older participants, we also found that elevated PGRS was modestly associated with HV in healthy individuals under age 35 years, an age at which Ab accumulation is very unlikely. 35, 36 Thus, PGRS may also have an effect via non-Ab pathways. It has become increasingly clear that additional factors beyond Ab influence the emergence of clinical symptoms of AD dementia, which may include developmental factors, the spread of tau into neocortex, or inflammatory responses. [37] [38] [39] The involvement of non-Ab processes in AD risk may explain why a portion of older individuals are able to function normally despite high quantities of Ab, which has important implications for mechanisms of disease resilience. Our study has several limitations. Given the relatively small sample size, it will be important to replicate these findings in independent samples. The associations identified between PGRS and AD markers were small, accounting for 1.0%-3.2% of the variance among the older group without dementia, and only 0.2% of the variance in HV within the younger group. However, these effect sizes are consistent with other biomarker studies assessing common genetic variants among older 40 and younger participants. 41 The smaller sample size within ADNI may have provided insufficient power to detect a statistically significant effect on Ab in the ADNI1 CSF sample. However, examination of the larger florbetapir ADNI dataset provided support for an association between PGRS and Ab among individuals without dementia. 
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